Journal
JOURNAL OF PEDIATRICS
Volume 238, Issue -, Pages 102-+Publisher
MOSBY-ELSEVIER
DOI: 10.1016/j.jpeds.2021.07.019
Keywords
-
Categories
Funding
- National Institute of Neurological Disorders and Stroke (NINDS) [U01NS077955, U01NS077953]
Ask authors/readers for more resources
The study aimed to test whether increased iron dose is linked to improved neurodevelopment in preterm infants enrolled in the Epo Neuroprotection Trial. Results showed a significant positive association between iron dose at 60 days and cognitive scores, but no significant impact at 90 days. Infants treated with Epo showed consistently greater effect sizes compared to those treated with placebo.
Objectives To test whether an increased iron dose is associated with improved neurodevelopment as assessed by the Bayley Scales of Infant Development, third edition (BSID-III) among infants enrolled in the Preterm Erythropoietin (Epo) Neuroprotection Trial (PENUT). Study design This is a post hoc analysis of a randomized trial that enrolled infants born at 24-28 completed weeks of gestation. All infants in PENUT who were assessed with BSID-III at 2 years were included in this study. The associations between enteral iron dose at 60 and 90 days and BSID-III component scores were evaluated using generalized estimating equations models adjusted for potential confounders. Results In total, 692 infants were analyzed (355 placebo, 337 Epo). Enteral iron supplementation ranged from 0 to 14.7 mg/kg/d (IQR 2.1-5.8 mg/kg/d) at day 60, with a mean of 3.6 mg/kg/d in infants treated with placebo and 4.8 mg/kg/d in infants treated with Epo. A significant positive association was seen between BSID-III cognitive scores and iron dose at 60 days, with an effect size of 0.77 BSID points per 50 mg/kg increase in cumulative iron dose (P =.03). Greater iron doses were associated with greater motor and language scores but did not reach statistical significance. Results at 90 days were not significant. The effect size in the infants treated with Epo compared with placebo was consistently greater. Conclusions A positive association was seen between iron dose at 60 days and cognitive outcomes. Our results suggest that increased iron supplementation in infants born preterm, at the doses administered in the PENUT Trial, may have positive neurodevelopmental effects, particularly in infants treated with Epo.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available